HomeChina: Anpac Bio-Medical to float on Nasdaq
ArticlesNews

China: Anpac Bio-Medical to float on Nasdaq

By Adrian Murdoch
-
Chief executive Chris Yu inspects Anpac Bio's proprietary cancer differentiation analysis liquid biopsy technology

Cancer-screening diagnostics company Anpac Bio-Medical plans to raise up to US$27m in an initial public offering on Nasdaq. The Lishui-based company is selling 1.7 million American Depository Shares at a…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Subscribe
Already have an account?
Previous article
India: IHH acquisition of Fortis hits roadblock
Next article
Europe: Credit Suisse poaches Friedrich von Schwedler
Adrian Murdoch
Adrian Murdoch
Adrian is a financial editor and journalist with more than 25 years of experience. He was the winner of the State Street Best Editorial Comment of the Year at the UK Institutional Press Awards 2023 and CFA UK ESG, Climate and Sustainable Investing Journalism Award 2023. He is the former editor of Capital Monitor at New Statesman Media, Healthcare Markets International in London (PPA Independent Publisher Awards finalist for Launch of the Year 2019) and international editor at FinanceAsia. A former Senior Correspondent for Reuters Insider Television in Frankfurt, and Screens Editor, Asia, for International Financing Review in Singapore, Adrian started his career at World Link, the magazine of the World Economic Forum.
Related Articles
More From Author

…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Subscribe
Already have an account?

…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Subscribe
Already have an account?
Advertisement

Related Resources

Related Events